In a report released today, Sean Lee CFA from H.C. Wainwright reiterated a Buy rating on Senseonics Holdings, with a price target of $1.40.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sean Lee CFA has given his Buy rating due to a combination of factors, primarily focusing on Senseonics Holdings’ strong financial performance and promising future prospects. The company reported a notable revenue growth of 37% year-over-year in the second quarter of 2025, driven by new patients switching to the Eversense 365 system. Management anticipates continued growth in the second half of 2025, particularly in the fourth quarter, as more patients reach their renewal dates. Additionally, the company has improved its gross margins significantly, which is expected to contribute positively to its financial health.
Another key factor influencing the Buy rating is the anticipated approval and launch of the Eversense 365 in the European Union. This expansion is seen as a crucial step towards increasing the company’s user base, despite the EU market being smaller than the U.S. Moreover, the initiation of a pivotal clinical study for the next-generation Gemini system is expected later this year. This system could cater to the needs of type 2 diabetes patients, who form a significant portion of the new Eversense users. These strategic initiatives are expected to bolster Senseonics’ market position and drive long-term growth.